Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2000-03-03
2003-09-02
Tate, Christopher R. (Department: 1651)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S094100, C424S094300
Reexamination Certificate
active
06613322
ABSTRACT:
BACKGROUND OF THE INVENTION
Throughout this application, various publications are referenced by author and date. Full citations for these publications may be found listed alphabetically at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art.
A key early event in atherogenesis is the subendothelial retention of atherogenic lipoproteins, including LDL
1
(Schwenke et al., 1989; Nievelstein et al., 1991), lipoprotein(a) [Lp(a)] (Kreuzer et al., 1994), and triglyceride-rich lipoproteins (Rapp et al., 1994). Atherosclerosis-susceptible regions of the arterial tree are distinguished by their increased retention of lipoproteins compared with resistant regions (Schwenke et al., 1989). The retained lipoproteins are likely to trigger a set of biological responses, such as lipoprotein oxidation and endothelial changes (Steinberg et al., 1989; Ross, 1995), that are central to the atherogenic process (Williams et al., 1995).
Lipoproteins retained in the subendothelium are often extensively aggregated (Nievelstein et al., 1991; Hoff et al., 1985; Guyton et al., 1996). For example, Hoff and colleagues and others (see Hoff et al., 1985; Guyton et al., 1996) have shown that LDL extracted from atherosclerotic lesions is aggregated or has an increased tendency to aggregate, whereas plasma LDL exposed to the same extraction procedure as a control does not aggregate. Furthermore, Frank and colleagues (Nievelstein et al., 1991) used freeze-etch electron microscopy to demonstrate aggregated LDL in the subendothelium of the rabbit aorta as early as two hours after a large bolus injection of human LDL. Subendothelial lipoprotein aggregation is likely to be important in atherogenesis for at least two reasons. First, processes that promote lipoprotein aggregation before or during retention would be expected to increase the amount of material retained (Tabas et al., 1993). Second, aggregated LDL, but not unaggregated LDL, is a potent inducer of macrophage foam cell formation (Hoff et al., 1990; Khoo et al., 1988; Suits et al., 1989; Xu et al., 1991).
SUMMARY OF THE INVENTION
The present invention provides for a method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase activity which comprises administering to the subject an amount of a zinc sphingmyelinase inhibitor effective to decrease extracellular zinc sphingomyelinase activity in the subject and thereby treat the subject. The present invention also provides for a method for determining whether a compound inhibits an activity of an extracellular zinc sphingomyelinase involving ceramide formation which comprises: (a) contacting a sample containing the zinc sphingomyelinase under acidic pH conditions known to be associated with the activity of such zinc sphingomyelinase, with: (i) a substrate of the zinc sphingomyelinase enzyme, and (ii) the compound being evaluated; (b) measuring the concentration of ceramide in the sample from (a); (c) determining the amount of zinc sphingomyelinase activity in the sample based upon the concentration of ceramide measured in step (b); and (d) comparing the amount of sphingomyelinase activity determined in step (c) with the amount of sphingomyelinase activity determined in the absence of the compound, so as to determine whether the compound inhibits the activity of zinc sphingomyelinase.
REFERENCES:
patent: 4766111 (1988-08-01), Catsimpoolas
patent: 5916911 (1999-06-01), Shayman et al.
patent: 5919687 (1999-07-01), Chatterjee
patent: 1152632 (1986-07-01), None
patent: 6211668 (1994-08-01), None
patent: 7258132 (1995-10-01), None
patent: 7285957 (1995-10-01), None
patent: 8053387 (1996-02-01), None
patent: 8113535 (1996-05-01), None
patent: 8134002 (1996-05-01), None
Schissel et al. Circulation, vol. 94, No. 8, Abstract # 0883, 1996.*
Schissel et al. Dissertation Abstracts, vol. 58, No. 9B, 167 pages, DISSABSabstract enclosed, 1997.*
Schissel et al. J. Biol. Chem. vol. 273, No. 5, pp. 2738-2746, Caplus abstract enclosed, 1998.*
Faust, P.L., Wall, D.A., Perara, E., Lingappa, V.R., and Kornfeld, S. (1987)J. Biol. Chem. 269, 22477-22480.
Hannun, Y. A. and R. M. Bell. 1989. Functions of sphingolipids and sphingolipid breakdown products in cellular regulation.Science243:500-507.
Kolesnick, R. N. 1991. Sphingomyelin and derivatives as cellular signals.Prog. Lipid Res. 30:1-38.
Levade, T., Salvayre, R., and Blazy-Douste, L. (1986)J. Clin. Chem. Biochem. 24, 205-220.
Okwu, A. K., X. Xu, Y. Shiratori, and I. Tabas. 1994. Regulation of the threshold for lipoprotein-induced acyl-CoA:cholesterol O-acyltransferase stimulation in macrophages by cellular sphingomyelin content.J. Lipid Res. 35:644-655.
Schissel, S. L., E. H. Schuchman, K. J. Williams, and I. Tabas. 1996. Zn2+-stimulated sphingomyelinase is secreted by many cell types and is a product of the acid sphingomyelinase gene.J. Biol. Chem.
Schissel, S. L., Schuchman, E. H., Williams, K. J., and Tabas, I. (1996)J. Biol. Chem. 271, 18431-18436.
Schissel, S. L., J. Tweedie-Hardman, J. H. Rapp, G. Graham, K. J. Williams, and I. Tabas. 1996. Rabbit aorta and human atherosclerotic lesions hydolyze the sphingomyelin of retained low-density lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins.J. Clin. Invest. 98:1455-1464.
Schuchman, E. H., M. Suchi, T. Takahashi, K. Sandhoff, and R. J. Desnick. 1991. Human acid sphingomyelinase. Isolation, nucleotide sequence, and expression of the full-length and alternatively spliced cDNAs.J. Biol. Chem. 266:8531-8539.
Skiba, P. J., X. Zha, S. L. Schissel, F. R. Maxfield, and I. Tabas. 1996. The distal pathway of lipoprotein-induced cholesterol esterification, but not sphingomyelinase-induced cholesterol esterification, is energy-dependent.J. Biol. Chem. 271:13392-13400.
Spence, M. W., D. M. Byers, F. B. St.C.Palmer, and H. W. Cook. 1989. A new Zn2+-stimulated sphingomyelinase in fetal bovine serum.J. Biol. Chem. 264:5358-5363.
Tabas, I., Y. Li, R. W. Brocia, S. W. Wu, T. L. Swenson, and K. J. Williams. 1993. Lipoprotein lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth muscle cells and extracellular matrix. A possible mechanism for low density lipoprotein and lipoprotein(a) retention and macrophage foam cell formation.J. Biol. Chem. 268:20419-20432.
Williams, K. J., G. M. Fless, K. A. Petrie, M. L. Snyder, R. W. Brocia, and T. L. Swenson. 1992. Mechanisms by which lipoprotein lipase alters cellular metabolism of lipoprotein(a), low density lipoprotein, and nascent lipoproteins. Roles for low density lipoprotein receptors and heparan sulfate proteoglycans.J. Biol. Chem. 267:13284-13292.
Williams, K. J. and I. Tabas. 1995. The response-to-retention hypothesis of early atherogenesis.Arterioscler. Thromb. Vasc. Biol. 15:551-561.
Xu, X. and I. Tabas. 1991. Sphingomyelinase enhances low density lipoprotein uptake and ability to induce cholesteryl ester accumulation in macrophages.J. Biol. Chem. 266:24849-24858.
Yamamoto, K. (1994)J. Biochem. 116, 229-235.
Schissel Scott L.
Tabas Ira
Williams Kevin Jon
Cooper & Dunham LLP
Tate Christopher R.
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Method for treating a subject suffering from conditions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating a subject suffering from conditions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating a subject suffering from conditions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3060745